GOLD 2026 COPD Guidelines: Triple Therapy, Biologics, and Exacerbation Prevention

GOLD 2026: Key Framework Changes

COPD management has become more nuanced and more effective over the past several years, and the 2026 GOLD report reflects that evolution. For the pulmonologist or primary care physician managing a panel of COPD patients, the key question has shifted from "does this patient need an inhaler?" to "which combination of therapies will best prevent exacerbations, preserve lung function, and reduce mortality for this specific patient's disease phenotype?" The 2026 update provides a clearer framework for answering that question, particularly around when to escalate to triple therapy and which patients might benefit from the emerging class of biologic therapies.

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 report refines the ABE assessment tool introduced in 2023, with updated thresholds for exacerbation risk stratification and expanded pharmacotherapy recommendations. The most significant changes include earlier positioning of triple therapy and the first mention of biologic therapies for select COPD phenotypes (for pediatric asthma biologics, see our dedicated review).

Triple Therapy: LAMA/LABA/ICS Positioning

The IMPACT and ETHOS trials established that triple therapy (fluticasone furoate/umeclidinium/vilanterol or budesonide/glycopyrrolate/formoterol) reduces exacerbations and all-cause mortality compared to dual bronchodilation[1][2] in patients with elevated eosinophils (above 100 cells/mcL) and frequent exacerbations. The 2026 guidelines now recommend earlier escalation to triple therapy for Group E patients with blood eosinophils above 100.

The Eosinophil Threshold in Clinical Practice

The eosinophil count of 100 cells/mcL as the threshold for considering ICS-containing regimens is a practical and evidence-based simplification. In clinical practice, this means checking a complete blood count with differential — something most COPD patients already have — and using the absolute eosinophil count to guide therapy selection. A patient with Group E COPD (two or more moderate exacerbations, or one hospitalized exacerbation, in the past year) and eosinophils above 100 should be considered for triple therapy rather than remaining on LAMA/LABA dual bronchodilation alone. Patients with eosinophils below 100 are less likely to benefit from the ICS component and may be better served by dual bronchodilation plus other non-pharmacologic exacerbation prevention strategies.

The emphasis on eosinophil-guided therapy reflects a broader shift in COPD management toward phenotype-driven treatment decisions. Not all COPD is the same. The patient with predominantly neutrophilic airway inflammation, frequent bacterial exacerbations, and low eosinophils needs a different treatment approach than the patient with high eosinophils, seasonal exacerbation patterns, and features of asthma-COPD overlap. The eosinophil count is an imperfect but useful proxy for identifying patients with a type 2 inflammatory component who are most likely to respond to ICS-containing regimens.

Single-Inhaler Triple Therapy: Simplifying the Regimen

One of the most practical advances in COPD pharmacotherapy is the availability of single-inhaler triple therapy devices. Adherence in COPD is notoriously poor — patients managing multiple inhalers with different dosing schedules and device techniques frequently use one or more of their inhalers incorrectly or inconsistently. Consolidating LAMA, LABA, and ICS into a single inhaler eliminates this complexity and has been shown in real-world studies to improve adherence compared to multi-inhaler regimens. When escalating to triple therapy, the single-inhaler option should be the default unless there is a specific clinical reason to use separate devices.

Biologics in Eosinophilic COPD

Dupilumab (anti-IL-4/IL-13) demonstrated a 30% reduction in moderate-to-severe exacerbations in the BOREAS and NOTUS trials for patients with blood eosinophils 300 cells/mcL or higher already on triple therapy[3][4]. This represents the first biologic therapy with robust Phase 3 COPD data and is expected to receive FDA approval for this indication.

Who Is a Candidate for Biologic Therapy in COPD?

The candidate for dupilumab in COPD is narrower than the biologic-eligible population in asthma. The BOREAS and NOTUS trials specifically enrolled patients with blood eosinophils of 300 cells/mcL or higher who were already on maximized triple therapy and continued to exacerbate. This is the COPD patient who has been on the right inhalers with confirmed good technique and adherence, has had vaccinations updated, has participated in pulmonary rehabilitation, and still experiences two or more moderate exacerbations or one hospitalized exacerbation per year. Before considering biologic therapy, the clinician should systematically confirm that all standard measures have been optimized — adding a biologic to a patient who is not using their triple inhaler correctly or who has not been vaccinated represents a missed opportunity to address simpler interventions first.